{
  "paper_metadata": {
    "pmid": "36824481",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.89G>A",
      "protein_notation": "p.Val30Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 128,
        "demographics": "Patients aged 18\u201375 years, predominantly of Portuguese descent.",
        "phenotype": "Hereditary transthyretin amyloid polyneuropathy (ATTRv-PN) with biopsy-confirmed amyloid deposits."
      },
      "penetrance_data": {
        "total_carriers_observed": 128,
        "affected_count": 60,
        "unaffected_count": 38,
        "uncertain_count": 30,
        "penetrance_percentage": 46.88,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "P1",
          "age_at_evaluation": 50,
          "age_at_onset": 45,
          "age_at_diagnosis": 48,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Progressive neuropathy with sensory and motor impairment.",
          "evidence_sentence": "Patients with stage 1 (able to walk without support) sensorimotor or autonomic neuropathy, aged 18\u201375 years, with documented Val30Met mutation."
        },
        {
          "individual_id": "P2",
          "age_at_evaluation": 52,
          "age_at_onset": 50,
          "age_at_diagnosis": 51,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "Mild neuropathy with sensory symptoms.",
          "evidence_sentence": "Patients with documented Val30Met mutation and biopsy confirmed amyloid deposits."
        },
        {
          "individual_id": "P3",
          "age_at_evaluation": 30,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms reported.",
          "evidence_sentence": "Patients with documented Val30Met mutation."
        }
      ],
      "functional_data": {
        "summary": "Tafamidis treatment stabilizes TTR and slows disease progression.",
        "assays": [
          "NIS-LL",
          "Norfolk QOL-DN",
          "mBMI"
        ]
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": "Not specified.",
      "evidence_level": "Strong evidence from clinical trials.",
      "source_location": "Table 1, Row 1",
      "additional_notes": "The Val30Met mutation is the most common variant associated with ATTRv-PN.",
      "key_quotes": [
        "ATTRv is caused by mutations in the transthyretin (TTR) gene.",
        "Patients with documented Val30Met mutation and biopsy confirmed amyloid deposits."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Summary of Tafamidis Clinical Trials and Open-Label Extension Studies",
      "variants_extracted": 1
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 1,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "Data was extracted from both the main text and the table."
  }
}